Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response.

Oberson A, Spagnuolo L, Puddinu V, Barchet W, Rittner K, Bourquin C.

Oncotarget. 2017 Dec 15;9(5):5641-5651. doi: 10.18632/oncotarget.23725. eCollection 2018 Jan 19.

2.

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.

Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K.

Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18.

3.

Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.

Schaedler E, Remy-Ziller C, Hortelano J, Kehrer N, Claudepierre MC, Gatard T, Jakobs C, Préville X, Carpentier AF, Rittner K.

Vaccine. 2017 Jan 23;35(4):577-585. doi: 10.1016/j.vaccine.2016.12.020. Epub 2016 Dec 21.

PMID:
28012777
4.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB.

Oncoimmunology. 2016 Sep 9;5(10):e1220467. eCollection 2016.

5.

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand.

Préville X, Rittner K, Fend L.

Oncoimmunology. 2015 Feb 3;4(5):e1003013. eCollection 2015 May.

6.

Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.

Fend L, Gatard-Scheikl T, Kintz J, Gantzer M, Schaedler E, Rittner K, Cochin S, Fournel S, Préville X.

Cancer Immunol Res. 2014 Dec;2(12):1163-74. doi: 10.1158/2326-6066.CIR-14-0050. Epub 2014 Aug 28.

7.

Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.

Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K.

J Virol. 2014 May;88(10):5242-55. doi: 10.1128/JVI.03819-13. Epub 2014 Feb 26.

8.

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

Amiset L, Fend L, Gatard-Scheikl T, Rittner K, Duong V, Rooke R, Muller S, Bonnefoy JY, Préville X, Haegel H.

Oncoimmunology. 2012 Nov 1;1(8):1271-1280.

9.

Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies.

Rittner K, Schreiber V, Erbs P, Lusky M.

Cancer Gene Ther. 2007 May;14(5):509-18. Epub 2007 Feb 23.

PMID:
17318198
10.

Ligation of exogenous linear DNA after gene transfer in vitro and in vivo.

Rittner K, Benavente A, Jacobs E.

J Gene Med. 2003 Sep;5(9):818-24.

PMID:
12950072
11.

New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo.

Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, Jacobs E.

Mol Ther. 2002 Feb;5(2):104-14.

12.

Novel tools for production and purification of recombinant adenoassociated virus vectors.

Grimm D, Kern A, Rittner K, Kleinschmidt JA.

Hum Gene Ther. 1998 Dec 10;9(18):2745-60.

PMID:
9874273
13.

Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids.

Längle-Rouault F, Patzel V, Benavente A, Taillez M, Silvestre N, Bompard A, Sczakiel G, Jacobs E, Rittner K.

J Virol. 1998 Jul;72(7):6181-5.

14.

In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M.

J Virol. 1998 Mar;72(3):2022-32.

16.
18.
20.
21.
22.

Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1.

Sczakiel G, Homann M, Rittner K.

Antisense Res Dev. 1993 Spring;3(1):45-52.

PMID:
8495105
23.
24.

Antisense RNA-mediated inhibition of the replication of the human immunodeficiency virus type 1. Discussion of critical parameters.

Sczakiel G, Pawlita M, Rittner K, Homann M.

Ann N Y Acad Sci. 1992 Oct 28;660:268-70. No abstract available.

PMID:
1340130
25.
26.

Replication of the human immunodeficiency virus type 1 is inhibited in human cells with antisense RNA expression.

Sczakiel G, Rittner K, Homann M, Pawlita M.

Biochem Soc Trans. 1991 Nov;19(4):437S. No abstract available.

PMID:
1794555
27.

Replication of the human immunodeficiency virus type 1 is inhibited by the adeno-associated virus rep gene.

Rittner K, Heilbronn R, Kleinschmidt JA, Oelze I, Sczakiel G.

Biochem Soc Trans. 1991 Nov;19(4):438S. No abstract available.

PMID:
1665443
28.
29.

The social context of active distress in patients with early myocardial infarction.

Siegrist J, Dittmann K, Rittner K, Weber I.

Soc Sci Med. 1982;16(4):443-53.

PMID:
7079798
30.

[Premature myocardial infarct and social stress].

Dittmann K, Rittner K, Weber I, Siegrist J.

MMW Munch Med Wochenschr. 1981 Nov 27;123(48):1841-2. German. No abstract available.

PMID:
6796861

Supplemental Content

Loading ...
Support Center